Based on the available information, there is no specific date found regarding when Apotex's Ruxolitinib ANDA (Abbreviated New Drug Application) was filed. However, the following information can be provided:

Ruxolitinib is a drug used to treat certain types of myelofibrosis, a bone marrow disorder, and polycythemia vera, a type of blood cancer. It is marketed under the brand name Jakafi by Incyte Corporation.

Apotex, a Canadian-based pharmaceutical company, is known for submitting ANDA applications to the U.S. Food and Drug Administration (FDA) for generic drug approvals.

The FDA website provides a list of approved generic drugs, but it does not offer specific filing dates for ANDA applications. The FDA states that once a generic drug application has been approved, it is listed on the agency's website along with the approval date. However, the list does not include the filing date.

Health Canada's website provides a list of generic submissions under review, but it does not include the filing date for Apotex's Ruxolitinib ANDA.

In summary, while it is not possible to provide the exact filing date for Apotex's Ruxolitinib ANDA, the information available indicates that Apotex, a reputable pharmaceutical company, has likely submitted an ANDA for a generic version of Ruxolitinib.

Sources:

1. <https://www.drugpatentwatch.com/p/tradename/RUXOLITINIB>
2. <https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/patent-certifications-and-suitability-petitions>
3. <https://www.canada.ca/en/health-canada/services/drug-health-product-review-approval/generic-submissions-under-review.html>